The Ketamine Revolution: How Science Is Redesigning Antidepressants

Ketamine revolutionized the treatment of depression by acting within hours, but its mechanism of action in the brain remained a mystery. Now, scientists have identified the specific neural circuits and receptors responsible for its rapid antidepressant effects. More importantly, the study has paved the way for the development of new antidepressants with the same efficacy but fewer side effects.

Depression is one of the most common and debilitating mental disorders in the world, but current treatments still have many limitations. Many antidepressants take weeks to take effect and don't always work for all patients.

In recent years, ketamine has attracted the attention of the scientific community for its ability to reduce depressive symptoms extremely quickly, sometimes in just a few hours.

Despite this impressive effect, researchers still didn't fully understand how the drug acted in the brain. Understanding this mechanism could pave the way for more effective treatments with fewer side effects.

In this study, scientists decided to investigate in detail which brain cells and molecular mechanisms are behind the antidepressant effect of ketamine. To do this, they used animal models subjected to chronic stress, a condition frequently used in the laboratory to reproduce brain changes similar to those observed in human depression.

The main focus of the research was a region called the medial prefrontal cortex, an area essential for emotional control, decision-making, and mood regulation. Alterations in this region are frequently found in people with depression.

The researchers discovered that ketamine depends on the activation of mu opioid receptors, proteins located on the surface of specific nerve cells in the brain. These receptors were especially concentrated in a group of neurons called interneurons that produce somatostatin.

These cells act as "brakes" on brain activity, helping to control the balance of neural circuits. Under normal conditions, they regulate the activity of pyramidal neurons, responsible for transmitting information between different regions of the brain. However, after long periods of stress, these interneurons undergo significant structural changes and end up excessively inhibiting the brain circuits linked to mood and motivation.

To understand these changes, scientists analyzed the microscopic structure of neural connections. They observed that chronic stress increased the size and activity of the presynaptic terminals of these interneurons, excessively strengthening the inhibitory signals sent to the pyramidal neurons.

Ketamine was able to reverse this process, restoring the balance of brain communication. This helped researchers understand that the antidepressant effects of the drug depend not only on a general chemical action in the brain, but on very specific changes in certain neural circuits.

The study also showed that the combined activation of multiple receptors produced antidepressant effects similar to those of ketamine, but with fewer adverse effects. This is particularly important because, although effective, ketamine can cause dissociation, perceptual alterations, and a risk of abuse.

The results suggest that it may be possible to develop new medications capable of reproducing the rapid antidepressant benefits of ketamine in a safer and more targeted way. Furthermore, the work offers a new strategy for identifying treatments for psychiatric illnesses through the detailed study of brain circuits and molecular communication between neurons.

READ MORE:

Mechanism-guided identification of antidepressant G protein-coupled receptor drug targets Hermany Munguba, Anisul Arefin, Ryota Hasegawa, Luca Posa, Giovanna R. Romano, Teja N. Peddada, Alexander Donatelle, Ashna Singh, Vanessa A. Gutzeit, Akshara Vijay, Prerana Vaddi, Melanie Kristt, Daniel Shaver, Shanjida Hoque, Johannes Broichhagen, Joseph M. Stujenske, Francis S. Lee, Evan O’Brien, Joshua Levitz, and Conor Liston.

Cell. Volume 189, Issue 9P2612-2632.E24. April 30, 2026

DOI:10.1016/j.cell.2026.04.006

Abstract: 

Depression is driven by dysfunction in discrete neural circuits, but a deeper understanding of the underlying molecular and synaptic mechanisms is needed to guide the development of therapeutics. Here, we decipher the mechanisms of action of the fast-acting antidepressant ketamine to enable the identification of G protein-coupled receptor (GPCR) antidepressant targets. We find that the behavioral effects of ketamine rely on mu-opioid receptors (MORs), which are enriched in somatostatin-expressing interneurons (Sst+ INs) in the medial prefrontal cortex (mPFC). Chronic stress drives presynaptic hypertrophy of mPFC Sst+ INs and excessive inhibition of pyramidal neurons, which is rescued by ketamine. Motivated by these findings, we use RNA sequencing to identify mPFC Sst+ IN-enriched GPCRs and validate the antidepressant potential of promising targets. Synergistic targeting of multiple GPCRs enables potent antidepressant-like responses with reduced side effects. Together, these findings reveal a general approach to identifying therapeutic GPCR targets for brain disorders.